Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Acadia Revives Nuplazid’s Chances In Schizophrenia With Negative Symptom Data

Executive Summary

After a Phase III failure in refractory schizophrenia, Acadia has Phase II data showing efficacy in negative symptoms of the disease, an unmet need. It plans a pivotal study in 2020.

You may also be interested in...



Acadia’s Nuplazid Shows Nearly Three-Fold Reduction In Psychosis Relapse

Data presented at the CTAD meeting for pimavanserin in dementia-related psychosis will support an sNDA filing in 2020 for an approval that could broaden the drug’s market exponentially.

Pimavanserin Fails In ENHANCE But Other CNS Uses Targeted

Acadia halts evaluation of pimavanserin as a schizophrenia adjunct but continues study of effect on negative symptoms and in other CNS conditions.

 

Allergan Seeks Quick Vraylar Turnaround After US FDA Refuses To File

Supplemental application for negative symptoms associated with schizophrenia has robust data, Datamonitor Healthcare analyst suggests, but was incomplete.

Topics

Related Companies

UsernamePublicRestriction

Register

SC141253

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel